Zimmer Biomet Announces Key Updates to Company's Executive Leadership Team
- Wilfred van Zuilen promoted to Group President, EMEA. Mark Bezjak promoted to President of the Americas. Nitin Goyal appointed to the Executive Leadership Team.
- None.
Wilfred van Zuilen Promoted to Group President, EMEA
Mark Bezjak Promoted to President of the
Chief Science, Technology and Innovation Officer Nitin Goyal, M.D. Appointed to Executive Leadership Team
"The expansion of Zimmer Biomet's Executive Leadership Team coincides with our renewed focus on commercial execution and innovation to drive the Company forward," said Mr. Tornos. "These appointments demonstrate the continued evolution of our business strategy as we remain focused on developing our team to drive value for patients, customers and all stakeholders."
Wilfred Van Zuilen Promotion to Group President, EMEA
Mr. van Zuilen joined Zimmer Biomet in June 2021 as President, EMEA. He will continue to be responsible for the sales, marketing and distribution of products in the EMEA region, and in his expanded role, he will also lead select global R&D projects.
Prior to joining Zimmer Biomet, Mr. van Zuilen served as Regional Vice President,
Mark Bezjak Promotion to President of the
Mark Bezjak joined Zimmer Biomet in April of 2008 as Director of Corporate Sales and has held roles of increasing importance with the Company, most recently serving as the President of
Prior to his work at Zimmer Biomet, Mr. Bezjak held multiple roles with Teleflex Medical and Michelin Tire Company. He holds a Bachelor of Science degree in Marketing from Virginia Tech and an MBA in Strategic Leadership from the University of
Nitin Goyal, M.D. Appointment to Executive Leadership Team
Dr. Goyal joined Zimmer Biomet in June 2021 in the newly created role of Chief Science, Technology and Innovation Officer. With his appointment, he will continue to have oversight of all global innovation, medical education, clinical affairs, and reimbursement strategy, now reporting to the President and CEO.
Dr. Goyal is a practicing adult hip and knee reconstruction surgeon. Prior to joining Zimmer Biomet, he also served as Chief Medical Officer and Senior Vice President of Innovation and Digital Care Delivery at Rally Health, part of the Optum business of UnitedHealth Group. Dr. Goyal is the Founder and CEO of Pulse Platform as well as Surgical Creations, leading both companies from inception to acquisition. He received his Bachelor's degree from Penn State University, his Medical degree from the Jefferson Medical College and completed his residency in Orthopedic Surgery and fellowship in Adult Reconstruction at the Rothman Institute and Thomas Jefferson University Hospital in
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "aims," "anticipates," "plans," "looking forward to," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "continue," "seeks" or the negatives of such terms or other variations on such terms or comparable terminology. Forward-looking statements include, but are not limited to, statements concerning the Company's expectations, plans, intentions, strategies, prospects, business plans, product and service offerings, new product launches, potential clinical successes, and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. Some of these risks and uncertainties can be found in Zimmer Biomet's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent periodic reports filed with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from the Company. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the Company's filings with the SEC. Such forward-looking statements speak only as of the date made, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to place undue reliance on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this press release.
Media | Investors | |
Meredith Weissman | Keri Mattox | |
(703) 346-3127 | (215) 275-2431 | |
Heather Zoumas-Lubeski (445) 248-0577 | Zach Weiner (908) 591-6955 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-key-updates-to-companys-executive-leadership-team-301917918.html
SOURCE Zimmer Biomet Holdings, Inc.
FAQ
Who has been promoted to Group President, EMEA?
Who has been promoted to President of the Americas?
Who has been appointed to the Executive Leadership Team?
Who do these executives report to?
What is the focus of these changes?
